In the current study, the fact that a down-regulation of CB1 and CB2 cannabinoid receptors is involved in the impaired nerve-evoked contractions from OZR bladder, reinforces the role of endocannabinoid system as an interesting and promising therapeutic target for MS-related bladder dysfunction. This evidence concerns the gene CNR1 and myeloid sarcoma.